Maurizio Fava
Affiliations: | MGH Depression Clinical and Research Program |
Area:
PsychiatryGoogle:
"Maurizio Fava"Cross-listing: Neurotree
Children
Sign in to add trainee| Roy H Perlis | post-doc | MGH (Neurotree) | |
| Y. Rachel Kim | post-doc | 2021- | Massachusetts General Hospital & Harvard Medical School (Neurotree) |
| Jonathan E. Alpert | research scientist | Harvard Medical School - Massachusetts General Hospital (Neurotree) | |
| Wasim Q. Malik | research scientist | Harvard Medical School (Neurotree) |
Collaborators
Sign in to add collaborator| Moshe Bar | collaborator | Harvard Medical School/ MGH (Neurotree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Murck H, Fava M, Cusin C, et al. (2023) Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study. Brain, Behavior, & Immunity - Health. 35: 100717 |
| Fava M. (2023) The challenges of defining and managing treatment-resistant depression in research and practice. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 22: 350-351 |
| Giles MA, Cooper CM, Jha MK, et al. (2023) Reward Behavior Disengagement, a Neuroeconomic Model-Based Objective Measure of Reward Pathology in Depression: Findings from the EMBARC Trial. Behavioral Sciences (Basel, Switzerland). 13 |
| Riesenberg R, Yeung PP, Rekeda L, et al. (2023) Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. 84 |
| Pilozzi A, Foster S, Mischoulon D, et al. (2023) A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression. International Journal of Molecular Sciences. 24 |
| Gomeni R, Bressolle-Gomeni F, Fava M. (2023) A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence. Psychiatry Research. 327: 115367 |
| Mac Giollabhui N, Mischoulon D, Dunlop BW, et al. (2023) Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial. Brain, Behavior, & Immunity - Health. 32: 100666 |
| Gomeni R, Bressolle-Gomeni F, Fava M. (2023) Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo. Translational Psychiatry. 13: 141 |
| Kim H, Jung JH, Han K, et al. (2023) Ages at menarche and menopause, hormone therapy, and the risk of depression. General Hospital Psychiatry. 83: 35-42 |
| Kim YR, Lauze MS, Slattery M, et al. (2023) Association Between Ghrelin and Body Weight Trajectory in Individuals With Anorexia Nervosa. Jama Network Open. 6: e234625 |